Disculpa, pero esta entrada está disponible sólo en Inglés Estadounidense. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.
The European Medicines Agency is developing a scheme to facilitate development and accelerated assessment of innovative medicines of major public health interest and in particular from the viewpoint of therapeutic innovation to address unmet needs. The criteria for accelerated assessment laid down in this guideline are being considered for the access to this scheme.